Clinical Trial Update: Ozurdex Monotherapy Trial [Phase 4]

View source ↗

Summary

The Phase 4 Ozurdex monotherapy trial for posterior uveitis, intermediate uveitis, and panuveitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermediate Uveitis
• Panuveitis
• Posterior Uveitis

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Uveitis, Posterior, Uveitis, Intermediate | Phase 4 | Status: WITHDRAWN